Results 71 to 80 of about 45,621 (284)

Targeting the Spliceosomal Protein USP39 Through Allosteric Ligands and PROTAC‐Induced Degradation

Angewandte Chemie International Edition, EarlyView.
Proteolysis‐targeting chimeras (PROTACs) enable degradation of proteins previously considered undruggable by harnessing the cellular ubiquitin–proteasome system. In this study, Schäfer et al. identify thiazole‐based small molecules that allosterically bind the zinc finger domain of ubiquitin‐specific protease 39 (USP39), a non‐enzymatic scaffold ...
Daniel Schäfer, Cristian Prieto‐Garcia, Jianhui Wang, Marcel Heinz, Vigor Matkovic, Pavel Kielkowski, Sebastian Hasselbeck, Varun Jayeshkumar Shah, Stefan Knapp, Gerhard Hummer, Ivan Dikic, Xinlai Cheng   +11 more
wiley   +1 more source

Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review

AIMS Molecular Science, 2022
Clopidogrel is a purinergic receptor P2Y12 (P2RY12)-blocking pro-drug used to inhibit platelet aggregation in patients at risk for major adverse cardiac events (MACE), such as coronary artery disease and stroke. Despite clopidogrel therapy, some patients
Rahel Tekeste, Gregorio Garza , Song Han, Jianli Dong   +3 more
doaj   +1 more source

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5‐year perspective from an EQA provider

British Journal of Clinical Pharmacology, EarlyView.
Aims Pharmacogenetic implementation requires awareness of the state‐of‐the‐art practice of laboratories providing pharmacogenetic testing. This study investigated how pharmacogenetic guidelines and recommendations have been implemented over time by Italian laboratories participating in the external quality assessment (EQA) Pharmaco‐scheme established ...
Rossana Roncato, Samantha Perfler, Diletta Pasin, Elena Peruzzi, Michael Woodcock, Henry Thomas, Rebecca Goodall, Simon J. Patton, Erika Cecchin   +8 more
wiley   +1 more source

Sertraline and Phenytoin Drug Interaction in a Geriatric Patient [PDF]

, 2017
This report presents the case of a 78-year-old man residing in a nursing home who presented with a 2-month history of increasing lethargy and confusion. These symptoms coincided with the initiation of sertraline in the patient.
Caprio, Thomas V., DiLoreto, Stefanie E., Hopkins, Heather A., Nathan, Kobi T, Ta, Nhon A.   +4 more
core   +2 more sources

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

Expert Opinion on Drug Metabolism & Toxicology, 2018
Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some patients do not respond adequately or develop treatment related adverse events. This
Nihal El Rouby, J. Lima, Julie A. Johnson   +2 more
semanticscholar   +1 more source

Omeprazole‐induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype [PDF]

British Journal of Clinical Pharmacology, 2010
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Omeprazole‐induced acute interstitial nephritis (OIAIN) is a rare adverse drug reaction. It is typically considered to be an idiosyncratic reaction affecting elderly patients. Omeprazole is a substrate for CYP2C19 and individuals who are homozygous variant for the null allele are poor metabolizers of this ...
Nuala A, Helsby, Wing-Yee, Lo, Ian J, Simpson, David M, Voss, Kaye E, Logan, Martin, Searle, John B W, Schollum, Janak R, de Zoysa   +7 more
openaire   +2 more sources

Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms

British Journal of Clinical Pharmacology, EarlyView.
Aim To characterize pharmacokinetic changes of sertraline and its metabolite during pregnancy and postpartum, and their relationship to maternal postpartum depressive symptoms. Methods This was a prospective observational, longitudinal study of pregnant women with a major depressive disorder treated with sertraline (N = 185 women, 205 pregnancies ...
Sílvia M. Illamola, Zachary N. Stowe, Marc L. Kalin, Michael D. Evans, Catherine M. Sherwin, Maged M. Costantine, D. Jeffrey Newport, James C. Ritchie, Angela K. Birnbaum   +8 more
wiley   +1 more source

Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype

Journal of Pharmacological Sciences, 2019
Polymorphisms of cytochrome P450 (CYP) enzymes can affect enzymatic activity, drug metabolism and drug interactions. Although the potential for drug interactions is especially important when co-administering drugs with strong inductive or inhibitory ...
Chiaki Kamiya, Naoki Inui, Akio Hakamata, Sachiko Miyakawa, Shimako Tanaka, Shinya Uchida, Noriyuki Namiki, Keiichi Odagiri, Hiroshi Watanabe   +8 more
doaj   +1 more source

Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe

European Journal of Human Genetics, 2019
CYP2C19 and CYP2D6 are important drug-metabolizing enzymes that are involved in the metabolism of around 30% of all medications. Importantly, the corresponding genes are highly polymorphic and these genetic differences contribute to interindividual and ...
J. Petrović, V. Pešić, V. Lauschke
semanticscholar   +1 more source

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source